Rhabdomyolysis caused by co-medication with simvastatin and clarithromycin.
Wagner
Judith
J
Suessmair
Christine
C
Pfister
Hans-Walter
HW
D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D017291:Clarithromycin / Q000009:adverse effects*; D000075202:Contraindications; D065692:Cytochrome P-450 CYP3A Inhibitors; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D007049:Iatrogenic Disease / Q000517:prevention & control; D018908:Muscle Weakness / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D012206:Rhabdomyolysis / Q000139:chemically induced*; D012307:Risk Factors; D019821:Simvastatin / Q000009:adverse effects*
D000900:Anti-Bacterial Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin; D017291:Clarithromycin